Anti-CD38 IgG1 monoclonal antibody (brand: Darzalex) that targets CD38 on AML cells, mediating ADCC, CDC, ADCP, and apoptosis, and depleting CD38+ immunosuppressive cells.
Human IgG1κ anti-CD38 monoclonal antibody that binds CD38 on tumor cells, inducing direct apoptosis and immune effector–mediated cytotoxicity (ADCC, CDC, ADCP), and depleting CD38+ immunosuppressive cells (e.g., Tregs, Bregs, MDSCs).
YES
DIRECT
Binds CD38 on target cells and induces killing via Fc-mediated ADCC (NK cells), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis.
An anti-CD38 antibody–drug conjugate comprising a human anti-CD38 monoclonal antibody covalently linked to a duostatin tubulin inhibitor; binds CD38 on malignant plasma cells, is internalized, and releases the duostatin payload to inhibit microtubule polymerization and induce apoptosis.
Fully human anti-CD38 antibody–drug conjugate that binds CD38 on malignant plasma cells, is internalized, and releases a duostatin/MMAF tubulin inhibitor payload to block microtubule polymerization, inducing G2/M arrest and apoptosis.
YES
DIRECT
The anti-CD38 ADC binds CD38, is internalized, and releases an MMAF/duostatin payload that inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD38+ cells.
An anti-CD38 antibody–drug conjugate comprising a human anti-CD38 monoclonal antibody covalently linked to a duostatin tubulin inhibitor; binds CD38 on malignant plasma cells, is internalized, and releases the duostatin payload to inhibit microtubule polymerization and induce apoptosis.
Fully human anti-CD38 antibody–drug conjugate that binds CD38 on malignant plasma cells, is internalized, and releases a duostatin/MMAF tubulin inhibitor payload to block microtubule polymerization, inducing G2/M arrest and apoptosis.
NO
INDIRECT
STI-6129 targets CD38 on cells, is internalized, and releases an MMAF/duostatin payload that binds beta-tubulin to inhibit microtubule polymerization, causing G2/M arrest and apoptosis; beta-tubulin expression alone does not make cells targets.
Gene-modified natural killer cells expressing a chimeric antigen receptor targeting CD19 to redirect NK cytotoxicity against CD19+ B cells; administered as cellular immunotherapy to deplete autoreactive B cells.
Gene-modified natural killer cells expressing an anti‑CD19 chimeric antigen receptor redirect NK cytotoxicity to CD19+ B cells in an MHC‑independent manner, inducing perforin/granzyme‑mediated killing of naive, memory, and plasmablast B‑cell subsets to deplete autoreactive B cells and reduce autoantibody production and B‑cell antigen presentation.
YES
DIRECT
Anti-CD19 CAR NK cells recognize CD19 on target cells and directly kill them via MHC-independent degranulation with perforin/granzyme-mediated apoptosis (and potentially death-receptor pathways).
An intravenously administered bispecific T-cell–engaging antibody that binds CD19 on B cells and CD3 on T cells, forming an immune synapse and activating TCR/CD3 signaling to drive T-cell–mediated cytotoxicity against malignant CD19+ B cells.
Intravenous bispecific antibody that binds CD19 on B cells and CD3 on T cells, creating an immune synapse that activates TCR/CD3 signaling and redirects T-cell cytotoxicity to eliminate malignant CD19+ B cells.
YES
DIRECT
The bispecific antibody bridges CD19 on target cells to CD3 on T cells, forming an immune synapse that activates TCR/CD3 signaling and redirects T-cell killing (perforin/granzyme-mediated apoptosis) of CD19+ cells.